An insight on drug resistance in Plasmodium vivax, a still neglected human malaria parasite

Abstract

References

1. REFERENCES
2. Krotoski WA, Garnham PC, Bray RS, Krotoski DM, Killick-Kendrick R, Draper CC, Targett GA, Guy MW. Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. Am J Trop Med Hyg. 1982 Jan;31(1):24-35.
3. Cogswell FB. The hypnozoite and relapse in primate malaria. Clin Microbiol Rev. 1992;5(1):26–35. doi:10.1128/cmr.5.1.26
4. Petersen E, Severini C, Picot S. Plasmodium vivax malaria: a re-emerging threat for temperate climate zones?. Travel Med Infect Dis. 2013;11(1):51–59. doi:10.1016/j.tmaid.2013.01.003
5. Piperaki ET, Daikos GL. Malaria in Europe: emerging threat or minor nuisance?. Clin Microbiol Infect. 2016;22(6):487–493. doi:10.1016/j.cmi.2016.04.023
6. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, Hay SI. Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95(6 Suppl):15-34. doi: 10.4269/ajtmh.16-0141.
7. Hupalo DN, Luo Z, Melnikov A, Sutton PL, Rogov P, Escalante A, Vallejo AF, Herrera S, Arévalo-Herrera M, Fan Q, Wang Y, Cui L, Lucas CM, Durand S, Sanchez JF, Baldeviano GC, Lescano AG, Laman M, Barnadas C, Barry A, Mueller I, Kazura JW, Eapen A, Kanagaraj D, Valecha N, Ferreira MU, Roobsoong W, Nguitragool W, Sattabonkot J, Gamboa D, Kosek M, Vinetz JM, González-Cerón L, Birren BW, Neafsey DE, Carlton JM. Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax. Nat Genet. 2016 Aug;48(8):953-8. doi: 10.1038/ng.3588.
8. World Health Organization . World Malaria Report 2019. Geneva, Switzerland: World Health Organization; 2019.
9. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295(6):302–304. doi:10.1056/NEJM197608052950602
10. Twohig KA, Pfeffer DA, Baird JK, Price RN, Zimmerman PA, Hay SI, Gething PW, Battle KE, Howes RE. Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLoS Negl Trop Dis. 2019 Jun 28;13(6):e0007525. doi: 10.1371/journal.pntd.0007525.
11. Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. Plasmodium vivax Infections of Duffy-Negative Erythrocytes: Historically Undetected or a Recent Adaptation? Trends Parasitol. 2018;34(5):420-429. doi: 10.1016/j.pt.2018.02.006
12. Zimmerman PA. Plasmodium vivax Infection in Duffy-Negative People in Africa. Am J Trop Med Hyg. 2017 Sep;97(3):636-638. doi: 10.4269/ajtmh.17-0461.
13. Baldari M, Tamburro A, Sabatinelli G, Romi R, Severini C, Cuccagna G, Fiorilli G, Allegri MP, Buriani C, Toti M. Malaria in Maremma, Italy. Lancet. 1998 Apr 25;351(9111):1246-7. doi:10.1016/S0140-6736(97)10312-9
14. Armengaud A, Legros F, Quatresous I, Barre H, Valayer P, Fanton Y, D'Ortenzio E, Schaffner F. A case of autochthonous Plasmodium vivax malaria, Corsica, August 2006. Travel Med Infect Dis. 2008 Jan-Mar;6(1-2):36-40. doi: 10.1016/j.tmaid.2007.09.042.
15. Santa-Olalla Peralta P, Vazquez-Torres MC, Latorre-Fandós E, Mairal-Claver P, Cortina-Solano P, Puy-Azón A, Adiego Sancho B, Leitmeyer K, Lucientes-Curdi J, Sierra-Moros MJ. First autochthonous malaria case due to Plasmodium vivax since eradication, Spain, October 2010. Euro Surveill. 2010;15(41):pii=19684.
16. Eurosurveillance editorial team. World Health Organization announces European Region malaria free. Euro Surveill. 2016;21(17):pii=30216. DOI: http://dx.doi. org/10.2807/1560-7917.ES.2016.21.17.30216
17. Andriopoulos P, Economopoulou A, Spanakos G, Assimakopoulos G. A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece—a re-emerging infection in the southern borders of Europe? Int J Infect Dis. 2013;17(2):e125–e128. doi:10.1016/j.ijid.2012.09.009
18. Ponçon N, Tran A, Toty C. A quantitative risk assessment approach for mosquito-borne diseases: malaria re-emergence in southern France. Malar J. 2008 Aug 1;7:147. doi: 10.1186/1475-2875-7-147.
19. Romi R, Boccolini D, Vallorani R, Severini F, Toma L, Cocchi M, Tamburro A, Messeri G, Crisci A, Angeli L, Costantini R, Raffaelli I, Pontuale G, Thiéry I, Landier A, Le Goff G, Fausto AM, Di Luca M. Assessment of the risk of malaria re-introduction in the Maremma plain (Central Italy) using a multi-factorial approach. Malar J. 2012 Mar 30;11:98. doi: 10.1186/1475-2875-11-98.
20. European Centre for Disease Prevention and Control. Multiple reports of locally-acquired malaria infections in the EU – 20 September 2017. ECDC: Stockholm; 2017.
21. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine?. Lancet. 1989;2(8673):1183–1184. doi:10.1016/s0140-6736(89)91792-3
22. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Oct;14(10):982-91. doi:10.1016/S1473-3099(14)70855-2.
23. World Health Organization. Guidelines for the Treatment of Malaria. 3rd edition. Geneva: World Health Organization; 2015. Annex 6, Treatment of Plasmodium vivax, P. ovale, P. malariae and P. knowlesi infections. Available from: https://www.ncbi.nlm.nih.gov/books/NBK294430/
24. Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, Yilma D, Batista Pereira D, Espino FEJ, Mia RZ, Chuquiyauri R, Val F, Casapía M, Monteiro WM, Brito MAM, Costa MRF, Buathong N, Noedl H, Diro E, Getie S, Wubie KM, Abdissa A, Zeynudin A, Abebe C, Tada MS, Brand F, Beck HP, Angus B, Duparc S, Kleim JP, Kellam LM, Rousell VM, Jones SW, Hardaker E, Mohamed K, Clover DD, Fletcher K, Breton JJ, Ugwuegbulam CO, Green JA, Koh GCKW. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.
25. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22(5):430–435. doi:10.1097/QCO.0b013e32832f14c1
26. Whitby M, Wood G, Veenendaal JR, Rieckmann K. Chloroquine-resistant Plasmodium vivax. Lancet. 1989;2(8676):1395. doi:10.1016/s0140-6736(89)92002-3
27. Baird, J. K., H. Basri, Purnomo, M. J. Bangs, B. Subianto, L. C. Patchen, and S. L. Hoffman. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 1991;44:547-552. doi:10.4269/ajtmh.1991.44.547
28. World Health Organization. Global report on antimalarial efficacy and drug resistance: 2000–2010. Geneva: World Health Organization; 2010.
29. Gonçalves LA, Cravo P, Ferreira MU. Emerging Plasmodium vivax resistance to chloroquine in South America: an overview. Mem Inst Oswaldo Cruz. 2014;109(5):534–539. doi:10.1590/0074-0276130579
30. Visser BJ, Wieten RW, Kroon D, Nagel IM, Bélard S, van Vugt M, Grobusch MP. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J. 2014;13:463. doi: 10.1186/1475-2875-13-463.
31. Tavul L, Hetzel MW, Teliki A, Walsh D, Kiniboro B, Rare L, Pulford J, Siba PM,Karl S, Makita L, Robinson L, Kattenberg JH, Laman M, Oswyn G, Mueller I.Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea. Malar J. 2018 Oct 5;17(1):350. doi: 10.1186/s12936-018-2494-z.
32. Sinclair D, Gogtay N, Brand F, Olliaro P. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008492. doi: 10.1002/14651858.CD008492.pub2.
33. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000;44(6):1680-5. doi: 10.1128/aac.44.6.1680-1685.2000.
34. Eibach D, Ceron N, Krishnalall K, Carter K, Bonnot G, Bienvenu AL, Picot S. Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. Malar J. 2012;11:347. doi: 10.1186/1475-2875-11-347.
35. Bassat Q. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis. 2011 Dec;5(12):e1325. doi: 10.1371/journal.pntd.0001325.
36. Senn N, Rarau P, Manong D, Salib M, Siba P, Reeder JC, Rogerson SJ, Genton B, Mueller I. Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea. Clin Infect Dis. 2013;56(10):1413-20. doi:10.1093/cid/cit068. Epub 2013 Feb 12.
37. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis. 1994;169(4):932–935. doi:10.1093/infdis/169.4.932
38. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10(10):673-81. doi: 10.1016/S1473-3099(10)70187-0.
39. Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, Sibley CH, Guerin PJ, Price RN. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(1):91-101. doi: 10.1016/S1473-3099(18)30596-6.
40. Rijal KR, Adhikari B, Ghimire P, Banjara MR, Das Thakur G, Hanboonkunupakarn B, Imwong M, Chotivanich K, Day NPJ, White NJ, Pukrittayakamee S. Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. J Infect Dis. 2019;220(3):448-456. doi: 10.1093/infdis/jiz126.
41. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010 Jun;10(6):405-16. doi: 10.1016/S1473-3099(10)70079-7.
42. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22(3):508–534. doi:10.1128/CMR.00008-09
43. Borlon C, Russell B, Sriprawat K, Suwanarusk R, Erhart A, Renia L, Nosten F, D'Alessandro U. Cryopreserved Plasmodium vivax and cord blood reticulocytes can be used for invasion and short term culture. Int J Parasitol. 2012;42(2):155-60. doi: 10.1016/j.ijpara.2011.10.011.
44. Udomsangpetch R, Kaneko O, Chotivanich K, Sattabongkot J. Cultivation of Plasmodium vivax. Trends Parasitol. 2008;24(2):85–88. doi:10.1016/j.pt.2007.09.010
45. Roobsoong W, Tharinjaroen CS, Rachaphaew N, Chobson P, Schofield L, Cui L, Adams JH, Sattabongkot J. Improvement of culture conditions for long-term in vitro culture of Plasmodium vivax. Malar J. 2015;14:297. doi: 10.1186/s12936-015-0815-z.
46. Rangel GW, Clark MA, Kanjee U, Lim C, Shaw-Saliba K, Menezes MJ, Mascarenhas A, Chery L, Gomes E, Rathod PK, Ferreira MU, Duraisingh MT. Enhanced Ex Vivo Plasmodium vivax Intraerythrocytic Enrichment and Maturation for Rapid and Sensitive Parasite Growth Assays. Antimicrob Agents Chemother. 2018;62(4):e02519-17. doi: 10.1128/AAC.02519-17.
47. Chaorattanakawee S, Lon C, Chann S, Thay KH, Kong N, You Y, Sundrakes S, Thamnurak C, Chattrakarn S, Praditpol C, Yingyuen K, Wojnarski M, Huy R, Spring MD, Walsh DS, Patel JC, Lin J, Juliano JJ, Lanteri CA, Saunders DL. Measuring ex vivo drug susceptibility in Plasmodium vivax isolates from Cambodia. Malar J. 2017;16(1):392. doi: 10.1186/s12936-017-2034-2.
48. Noulin F, Borlon C, Van Den Abbeele J, D'Alessandro U, Erhart A. 1912-2012: a century of research on Plasmodium vivax in vitro culture. Trends Parasitol. 2013;29(6):286–294. doi:10.1016/j.pt.2013.03.012.
49. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, Fidock DA, Su X, Collins WE, McCutchan TF, Wootton JC, Wellems TE. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis. 2001;183(11):1653-61. doi: 10.1086/320707.
50. Sá JM, Yamamoto MM, Fernandez-Becerra C, de Azevedo MF, Papakrivos J, Naudé B, Wellems TE, Del Portillo HA. Expression and function of pvcrt-o, a Plasmodium vivax ortholog of pfcrt, in Plasmodium falciparum and Dictyostelium discoideum. Mol Biochem Parasitol. 2006;150(2):219-28. doi: 10.1016/j.molbiopara.
51. Sá JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, Salzman RE, Gibson TJ, Velmurugan S, Krause MA, Melendez-Muniz V, Kite WA, Han PK, Eastman RT, Kim A, Kessler EG, Abebe Y, James ER, Chakravarty S, Orr-Gonzalez S, Lambert LE, Engels T, Thomas ML, Fasinu PS, Serre D, Gwadz RW, Walker L, DeConti DK, Mu J, Bailey JA, Sim BKL, Hoffman SL, Fay MP, Dinglasan RR, Juliano JJ, Wellems TE. Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. Nat Commun. 2019;10(1):4300. doi: 10.1038/s41467-019-12256-9.
52. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364(9432):438-447. doi: 10.1016/S0140-6736(04)16767-6.
53. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006;194(4):528–535. doi:10.1086/507115
54. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, Sutanto I, Peyron F, Picot S. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis. 2005 Jan 15;191(2):272-7. doi: 10.1086/426830.
55. Sá JM, Nomura T, Neves Jd, Baird JK, Wellems TE, del Portillo HA. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol. 2005;109(4):256–259. doi:10.1016/j.exppara.2004.12.005.
56. Picot S, Brega S, Gérôme P, et al. Absence of nucleotide polymorphism in a Plasmodium vivax multidrug resistance gene after failure of mefloquine prophylaxis in French Guyana. Trans R Soc Trop Med Hyg. 2005;99(3):234–237. doi:10.1016/j.trstmh.2004.09.007.
57. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One. 2007;2(10):e1089. doi: 10.1371/journal.pone.0001089.
58. Sow F, Bonnot G, Ahmed BR, Diagana SM, Kebe H, Koita M, Samba BM, Al-Mukhaini SK, Al-Zadjali M, Al-Abri SS, Ali OA, Samy AM, Hamid MM, Ali Albsheer MM, Simon B, Bienvenu AL, Petersen E, Picot S. Genetic diversity of Plasmodium vivax metacaspase 1 and Plasmodium vivax multi-drug resistance 1 genes of field isolates from Mauritania, Sudan and Oman. Malar J. 2017 Feb 2;16(1):61. doi: 10.1186/s12936-017-1687-1.
59. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother. 2001;45(11):3122-7. doi: 10.1128/AAC.45.11.3122-3127.2001.
60. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother. 2002;46(12):3947-53. doi: 10.1128/aac.46.12.3947-3953.2002.
61. de Pécoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol. 1998;92(2):265–273. doi:10.1016/s0166-6851(97)00247-8.
62. Marfurt J, de Monbrison F, Brega S, Barbollat L, Müller I, Sie A, Goroti M, Reeder JC, Beck HP, Picot S, Genton B. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis. 2008;198(3):409-17. doi: 10.1086/589882.
63. Menegon M, Majori G, Severini C. Genetic variations of the Plasmodium vivax dihydropteroate synthase gene. Acta Trop 2006, 98: 196-199
64. Imwong M, Pukrittayakamee S, Cheng Q, Moore C, Looareesuwan S, Snounou G, White NJ, Day NP. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob Agents Chemother. 2005;49(10):4393-5. doi: 10.1128/AAC.49.10.4393-4395.2005.
65. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50-5. doi: 10.1038/nature12876.
66. Popovici J, Kao S, Eal L, Bin S, Kim S, Ménard D. Reduced polymorphism in the Kelch propeller domain in Plasmodium vivax isolates from Cambodia. Antimicrob Agents Chemother. 2015;59(1):730–733. doi:10.1128/AAC.03908-14.
67. Wang M, Siddiqui FA, Fan Q, Luo E, Cao Y, Cui L. Limited genetic diversity in the PvK12 Kelch protein in Plasmodium vivax isolates from Southeast Asia. Malar J. 2016;15(1):537. Published 2016 Nov 8. doi:10.1186/s12936-016-1583-0.
68. Duanguppama J, Mathema VB, Tripura R, Day NPJ, Maxay M, Nguon C, von Seidlein L, Dhorda M, Peto TJ, Nosten F, White NJ, Dondorp AM, Imwong M. Polymorphisms in Pvkelch12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. Malar J. 2019 Apr 2;18(1):114. doi: 10.1186/s12936-019-2749-3.
69. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95:15–34.
70. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351. Published 2011 Dec 12. doi:10.1186/1475-2875-10-351.
71. Dijanic C, Nickerson J, Shakya S, Dijanic A, Fabbri M. Relapsing Malaria: A Case Report of Primaquine Resistance. Case Rep Infect Dis. 2018;2018:9720823. Published 2018 Mar 11. doi:10.1155/2018/9720823.
72. Huldén L, Huldén L, Heliövaara K. Natural relapses in vivax malaria induced by Anopheles mosquitoes. Malar J. 2008;7:64. Published 2008 Apr 22. doi:10.1186/1475-2875-7-64.
73. Hounkpatin AB, Kreidenweiss A, Held J. Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. Infect Drug Resist. 2019;12:553–570. Published 2019 Mar 6. doi:10.2147/IDR.S151031.
74. Medicines for Malaria Venture. MMV Annual Report 2016. Medicines for Malaria Venture. Available from: https://www.mmv.org/newsroom/ publications/mmv-annual-report-2016. Published June 14, 2018.